White paper on Ivermectin as a potential therapy for COVID-19
et al., Indian Journal of Tuberculosis, doi:10.1016/j.ijtb.2020.07.031, Jul 2020
Ivermectin for COVID-19
4th treatment shown to reduce risk in
August 2020, now with p < 0.00000000001 from 106 studies, recognized in 24 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
Panel review of ivermectin reporting that "ivermectin in the dose of 12mg BD alone or in combination with other therapy for 5-7 days may be considered as safe therapeutic option for mild moderate or severe cases of Covid-19 infection. It is cost effective especially when the other drugs are very costly & not easily available".
1.
Mothae et al., SARS-CoV-2 host-pathogen interactome: insights into more players during pathogenesis, Virology, doi:10.1016/j.virol.2025.110607.
2.
Zhang et al., Rho-GTPases subfamily: cellular defectors orchestrating viral infection, Cellular & Molecular Biology Letters, doi:10.1186/s11658-025-00722-w.
3.
Saha et al., Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral Pathogens, Viruses, doi:10.3390/v17020252.
4.
Ulloa-Aguilar et al., The Nucleolus and Its Interactions with Viral Proteins Required for Successful Infection, Cells, doi:10.3390/cells13181591.
5.
Enyeji et al., Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports, Viral Immunology, doi:10.1089/vim.2024.0034.
6.
Wimalawansa, S., Unlocking Insights: Navigating COVID-19 Challenges and Emulating Future Pandemic Resilience Strategies with Strengthening Natural Immunity, Heliyon, doi:10.1016/j.heliyon.2024.e34691.
7.
Shouman et al., SARS-CoV-2-associated lymphopenia: possible mechanisms and the role of CD147, Cell Communication and Signaling, doi:10.1186/s12964-024-01718-3.
8.
Mehraeen et al., Treatments for Olfactory Dysfunction in COVID-19: A Systematic Review, International Archives of Otorhinolaryngology, doi:10.1055/s-0044-1786046.
9.
Scheim et al., Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses, Viruses, doi:10.3390/v16040647.
10.
Yagisawa et al., Global trends in clinical trials of ivermectin for COVID-19—Part 2, The Japanese Journal of Antibiotics, doi:10.11553/antibiotics.77.1_45.
11.
Liu et al., Crosstalk between neutrophil extracellular traps and immune regulation: insights into pathobiology and therapeutic implications of transfusion-related acute lung injury, Frontiers in Immunology, doi:10.3389/fimmu.2023.1324021.
12.
Scheim (B) et al., Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19, International Journal of Molecular Sciences, doi:10.3390/ijms242317039.
13.
Yemeke et al., Impact of the COVID-19 pandemic on the quality of medical products in Zimbabwe: a qualitative study based on key informant interviews with health system stakeholders, BMJ Open, doi:10.1136/bmjopen-2022-068923.
14.
Kory, P., The Global War on Ivermectin, International Covid Summit III, European Parliament, Brussels, covid19criticalcare.com/wp-content/uploads/2023/05/GLOBAL-WAR-ON-IVERMECTIN-PARLIAMENT.pdf.
15.
Babalola et al., The Place of Ivermectin in the Management of Covid-19: State of the Evidence, Medical Research Archives, doi:10.18103/mra.v11i4.3778.
16.
Loo et al., Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections, Pharmaceutical Research, doi:10.1007/s11095-023-03520-1.
17.
Scheim (C), D., From Cold to Killer: How SARS-CoV-2 Evolved without Hemagglutinin Esterase to Agglutinate and Then Clot Blood Cells, Center for Open Science, doi:10.31219/osf.io/sgdj2.
18.
Kory (B), P., The Criminal Censorship of Ivermectin's Efficacy By The High-Impact Medical Journals - Part 1, Pierre Kory’s Medical Musings, pierrekory.substack.com/p/the-criminal-censorship-of-ivermectins.
19.
Al-kuraishy et al., Central effects of Ivermectin in alleviation of Covid-19-induced dysautonomia, Current Drug Targets, doi:10.2174/1389450123666220810102406.
20.
Schwartz, E., Does ivermectin have a place in the treatment of mild Covid-19?, New Microbes and New Infections, doi:10.1016/j.nmni.2022.100989.
21.
Marques et al., Ivermectin as a possible treatment for COVID-19: a review of the 2022 protocols, Brazilian Journal of Biology, doi:10.1590/1519-6984.258325.
22.
Semiz, S., SIT1 transporter as a potential novel target in treatment of COVID-19, Biomolecular Concepts, doi:10.1515/bmc-2021-0017.
23.
Zaidi et al., The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review, The Journal of Antibiotics, doi:10.1038/s41429-021-00491-6.
24.
Behl et al., CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target, Science of The Total Environment, doi:10.1016/j.scitotenv.2021.152072.
25.
Low et al., Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, doi:10.1016/j.bbadis.2021.166294.
26.
Fordham et al., The uses and abuses of systematic reviews, OSF Preprints, doi:10.31219/osf.io/mp4f2.
27.
Kow et al., Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001441.
28.
Santin et al., Ivermectin: a multifaceted drug of Nobel prize-honored distinction with indicated efficacy against a new global scourge, COVID-19, New Microbes and New Infections, doi:10.1016/j.nmni.2021.100924.
29.
Adegboro et al., A review of the anti-viral effects of ivermectin, African Journal of Clinical and Experimental Microbiology, doi:10.4314/ajcem.v22i3.2.
30.
Turkia, M., A Continuation of a Timeline of Ivermectin-Related Events in the COVID-19 Pandemic [June 30, 2021], ResearchGate, doi:10.13140/RG.2.2.16973.36326.
31.
Jagiasi et al., Variation in therapeutic strategies for the management of severe COVID-19 in India- A nationwide cross-sectional survey, The International Journal of Clinical Practice, doi:10.1111/ijcp.14574.
32.
Lind et al., Increase in Outpatient Ivermectin Dispensing in the US During the COVID-19 Pandemic: A Cross-Sectional Analysis, Journal of General Internal Medicine, doi:10.1007/s11606-021-06948-6.
33.
Wang et al., Minimum manufacturing costs, national prices and estimated global availability of new repurposed therapies for COVID-19, medRxiv, doi:10.1101/2021.06.01.21258147.
34.
Kory (C) et al., Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19, American Journal of Therapeutics, doi:10.1097/MJT.0000000000001377.
35.
DiNicolantonio et al., Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors, Open Heart, doi:10.1136/openhrt-2021-001655.
36.
Turkia (B), M., A timeline of ivermectin-related events in the COVID-19 pandemic, Research Gate, www.researchgate.net/publication/350610718_A_Timeline_of_Ivermectin-Related_Events_in_the_COVID-19_Pandemic_April_3_2021.
37.
Wehbe et al., Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities, Front. Immunol., doi:10.3389/fimmu.2021.663586.
38.
Yagisawa (B) et al., Global trends in clinical studies of ivermectin in COVID-19, The Japanese Journal of Antibiotics, 74-1, Mar 2021, jja-contents.wdc-jp.com/pdf/JJA74/74-1-open/74-1_44-95.pdf.
39.
Jans et al., The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?, Biochemical and Biophysical Research Communications, doi:10.1016/j.bbrc.2020.10.042.
40.
Kory (D) et al., Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19, Frontiers in Pharmacology, doi:10.3389/fphar.2021.643369.
41.
Formiga et al., Ivermectin: an award-winning drug with expected antiviral activity against COVID-19, J. Control Release, doi:10.1016/j.jconrel.2020.10.009.
42.
Scheim (D), D., Ivermectin for COVID-19 Treatment: Clinical Response at Quasi-Threshold Doses Via Hypothesized Alleviation of CD147-Mediated Vascular Occlusion, SSRN, doi:10.2139/ssrn.3636557.
43.
Turkia (C), M., FLCCC Alliance MATH+ ascorbic acid and I-MASK+ ivermectin protocols for COVID-19 — a brief review, ResearchGate, www.researchgate.net/profile/Mika_Turkia/publication/345694745_FLCCC_Alliance_MATH_ascorbic_acid_and_I-MASK_ivermectin_protocols_for_COVID-19_-_A_Brief_Review/links/5fab010f4585150781078260/FLCCC-Alliance-MATH-ascorbic-acid-and-I-MASK-ivermectin-protocols-for-COVID-19-A-Brief-Review.pdf.
44.
Jans (B) et al., Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?, Cells 2020, 9:9, 2100, doi:10.3390/cells9092100.
45.
Elkholy et al., Ivermectin: A Closer Look at a Potential Remedy, Cureus, doi:10.7759/cureus.10378.
46.
DiNicolantonio (B) et al., Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19, Open Heart, doi:10.1136/openhrt-2020-001350.
47.
Vora et al., White paper on Ivermectin as a potential therapy for COVID-19, Indian Journal of Tuberculosis, doi:10.1016/j.ijtb.2020.07.031.
Vora et al., 31 Jul 2020, peer-reviewed, 4 authors.
White paper on Ivermectin as a potential therapy for COVID-19
Indian Journal of Tuberculosis, doi:10.1016/j.ijtb.2020.07.031
A group of senior doctors with vast clinical experience met on 19th July'20 under the aegis of Academy of Advanced Medical Education. The panel looked at Ivermectin, one of the old molecule and evaluated it's use in COVID 19 (Novel Coronavirus Disease 2019) management. After critical panel discussion, all the attending doctors came to a conclusion that Ivermectin can be a potential molecule for prophylaxis and treatment of people infected with Coronavirus, owing to its anti-viral properties coupled with effective cost, availability and good tolerability and safety.
Author's contributions All authors provided critical feedback and contributed to the final manuscript.
Declaration of Competing Interest The authors have none to declare.
References
Banerjee, Nandy, Dalai, Ahmed, The battle against COVID 19 pandemic: what we need to know before we "test fire, Ivermectin. Drug Res, doi:10.1055/a-1185-8913
Caly, Druce, Catton, Jans, Wagstaff, The FDAapproved drug ivermectin inhibits the replication of SARS
Cherian, Agrawal, Basu, Abraham, Gangakhedkar et al., Perspectives for repurposing drugs for the coronavirus disease 2019, Indian J Med Res, doi:10.4103/ijmr.IJMR_585_20
Chowdhury, Shahbaz, Karim, Islam, Dan et al., A comparative observational study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients
David, What is the role of antiparasitic drug ivermectin in the treatment of corona virus disease
Gupta, Sahoo, Singh, Ivermectin: potential candidate for the treatment of Covid 19, Braz J Infect Dis
Guzzo, Furtek, Porras, Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J Clin Pharmacol, doi:10.1177/009127002401382731
Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot, doi:10.1038/s41429-020-0336-z
Mah Evas, Tran, Roumier, Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data, BMJ, doi:10.1136/bmj.m1844
Pal, Yadav, COVID-19 pandemic in India: present scenario and a steep climb ahead, J Prim Care Commun Health, doi:10.1177/2150132720939402
Patel, Desai, Grainger, Mehra, Usefulness of Ivermectin in COVID-19 Illness
Rajter, Sherman, Fatteh, Vogel, Sacks et al., ICON (Ivermectin in COvid Nineteen) study: use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19, doi:10.1101/2020.06.06.20124461
Romagnoli, Peris, Gaudio, Geppetti, SARS-CoV-2 and COVID-19: from the Bench to the bedside, Physiol Rev, doi:10.1152/physrev.00020.2020
Sharun, Dhama, Patel, Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19, Ann Clin Microbiol Antimicrob, doi:10.1186/s12941-020-00368-w
Sinhaa, Sehgalb, Sehgala, Ivermectin: is it to Be a potent therapeutic option for COVID-19?, Clin Infect Immun, doi:10.14740/cii106
Vora, Arora, Behera Academy of Advanced Medical Education
DOI record:
{
"DOI": "10.1016/j.ijtb.2020.07.031",
"ISSN": [
"0019-5707"
],
"URL": "http://dx.doi.org/10.1016/j.ijtb.2020.07.031",
"alternative-id": [
"S0019570720301025"
],
"author": [
{
"affiliation": [],
"family": "Vora",
"given": "Agam",
"sequence": "first"
},
{
"affiliation": [],
"family": "Arora",
"given": "V.K.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Behera",
"given": "D.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Tripathy",
"given": "Surya Kant",
"sequence": "additional"
}
],
"container-title": "Indian Journal of Tuberculosis",
"container-title-short": "Indian Journal of Tuberculosis",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2020,
8,
18
]
],
"date-time": "2020-08-18T12:33:38Z",
"timestamp": 1597754018000
},
"deposited": {
"date-parts": [
[
2022,
11,
7
]
],
"date-time": "2022-11-07T21:04:21Z",
"timestamp": 1667855061000
},
"funder": [
{
"DOI": "10.13039/100007028",
"doi-asserted-by": "publisher",
"name": "Helmsley Charitable Trust"
}
],
"indexed": {
"date-parts": [
[
2023,
10,
12
]
],
"date-time": "2023-10-12T01:28:25Z",
"timestamp": 1697074105687
},
"is-referenced-by-count": 17,
"issue": "3",
"issued": {
"date-parts": [
[
2020,
7
]
]
},
"journal-issue": {
"issue": "3",
"published-print": {
"date-parts": [
[
2020,
7
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://www.elsevier.com/tdm/userlicense/1.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2020,
7,
1
]
],
"date-time": "2020-07-01T00:00:00Z",
"timestamp": 1593561600000
}
}
],
"link": [
{
"URL": "https://api.elsevier.com/content/article/PII:S0019570720301025?httpAccept=text/xml",
"content-type": "text/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://api.elsevier.com/content/article/PII:S0019570720301025?httpAccept=text/plain",
"content-type": "text/plain",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "78",
"original-title": [],
"page": "448-451",
"prefix": "10.1016",
"published": {
"date-parts": [
[
2020,
7
]
]
},
"published-print": {
"date-parts": [
[
2020,
7
]
]
},
"publisher": "Elsevier BV",
"reference": [
{
"DOI": "10.1177/2150132720939402",
"article-title": "COVID-19 pandemic in India: present scenario and a steep climb ahead",
"author": "Pal",
"doi-asserted-by": "crossref",
"journal-title": "J Prim Care Commun Health",
"key": "10.1016/j.ijtb.2020.07.031_bib1",
"volume": "11",
"year": "2020"
},
{
"DOI": "10.14740/cii106",
"article-title": "Ivermectin: is it to Be a potent therapeutic option for COVID-19?",
"author": "Sinhaa",
"doi-asserted-by": "crossref",
"first-page": "51",
"issue": "2",
"journal-title": "Clin Infect Immun",
"key": "10.1016/j.ijtb.2020.07.031_bib2",
"volume": "5",
"year": "2020"
},
{
"DOI": "10.1186/s12941-020-00368-w",
"article-title": "Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19",
"author": "Sharun",
"doi-asserted-by": "crossref",
"first-page": "23",
"issue": "1",
"journal-title": "Ann Clin Microbiol Antimicrob",
"key": "10.1016/j.ijtb.2020.07.031_bib3",
"volume": "19",
"year": "2020"
},
{
"DOI": "10.1016/j.antiviral.2020.104787",
"article-title": "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro",
"author": "Caly",
"doi-asserted-by": "crossref",
"first-page": "104787",
"journal-title": "Antiviral Res",
"key": "10.1016/j.ijtb.2020.07.031_bib4",
"volume": "178",
"year": "2020"
},
{
"article-title": "The battle against COVID 19 pandemic: what we need to know before we “test fire” Ivermectin",
"author": "Banerjee",
"journal-title": "Drug Res (Stuttg)",
"key": "10.1016/j.ijtb.2020.07.031_bib5",
"year": "2020"
},
{
"author": "Chowdhury",
"key": "10.1016/j.ijtb.2020.07.031_bib6"
},
{
"DOI": "10.4103/ijmr.IJMR_585_20",
"article-title": "Perspectives for repurposing drugs for the coronavirus disease 2019",
"author": "Cherian",
"doi-asserted-by": "crossref",
"first-page": "160",
"issue": "2 & 3",
"journal-title": "Indian J Med Res",
"key": "10.1016/j.ijtb.2020.07.031_bib8",
"volume": "151",
"year": "2020"
},
{
"article-title": "Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data",
"author": "Mahévas",
"first-page": "m2328",
"journal-title": "BMJ",
"key": "10.1016/j.ijtb.2020.07.031_bib9",
"volume": "369",
"year": "2020"
},
{
"article-title": "Targeted Update: safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19",
"journal-title": "WHO",
"key": "10.1016/j.ijtb.2020.07.031_bib10",
"year": "2020"
},
{
"DOI": "10.1152/physrev.00020.2020",
"article-title": "SARS-CoV-2 and COVID-19: from the Bench to the bedside",
"author": "Romagnoli",
"doi-asserted-by": "crossref",
"journal-title": "Physiol Rev",
"key": "10.1016/j.ijtb.2020.07.031_bib11",
"volume": "100",
"year": "2020"
},
{
"article-title": "Ivermectin: potential candidate for the treatment of Covid 19",
"author": "Gupta",
"first-page": "30081",
"issue": "20",
"journal-title": "Braz J Infect Dis",
"key": "10.1016/j.ijtb.2020.07.031_bib12",
"volume": "S1413–8670",
"year": "2020"
},
{
"author": "Clinical Trials Registry- India",
"key": "10.1016/j.ijtb.2020.07.031_bib13"
},
{
"DOI": "10.1177/009127002401382731",
"article-title": "Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects",
"author": "Guzzo",
"doi-asserted-by": "crossref",
"first-page": "1122",
"issue": "10",
"journal-title": "J Clin Pharmacol",
"key": "10.1016/j.ijtb.2020.07.031_bib14",
"volume": "42",
"year": "2002"
},
{
"author": "Drugs@FDA: FDA-Approved Drugs",
"key": "10.1016/j.ijtb.2020.07.031_bib15"
},
{
"author": "Cennimo",
"key": "10.1016/j.ijtb.2020.07.031_bib18"
},
{
"author": "Rajter",
"key": "10.1016/j.ijtb.2020.07.031_bib19"
},
{
"author": "Patel",
"key": "10.1016/j.ijtb.2020.07.031_bib20",
"series-title": "Usefulness of Ivermectin in COVID-19 Illness",
"year": "2020"
},
{
"article-title": "To study the effectiveness of Ivermectin with standard of care treatment versus standard of care treatment for COVID 19 cases",
"journal-title": "A Pilot Study",
"key": "10.1016/j.ijtb.2020.07.031_bib22",
"year": "2019"
},
{
"article-title": "Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen",
"author": "Heidary",
"first-page": "1",
"journal-title": "J Antibiot (Tokyo)",
"key": "10.1016/j.ijtb.2020.07.031_bib23",
"year": "2020"
}
],
"reference-count": 19,
"references-count": 19,
"relation": {},
"resource": {
"primary": {
"URL": "https://linkinghub.elsevier.com/retrieve/pii/S0019570720301025"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "White paper on Ivermectin as a potential therapy for COVID-19",
"type": "journal-article",
"volume": "67"
}